Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 8, 2013, Pages 859-861

  Kuitwaard, Krista ^a   Van Doorn, Pieter A ^a   Vermeulen, Marinus ^b   Van Den Berg, Leonard H ^c   Brusse, Esther ^a   Van Der Kooi, Anneke J ^b   Van Der Pol, W Ludo ^c   Van Schaik, Ivo N ^b   Notermans, Nicolette ^c   Tio Gillen, Anne P ^a   Van Rijs, Wouter ^a   Van Gelder, Teun ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; GENERAL CONDITION DETERIORATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAINTENANCE THERAPY; MUSCLE WEAKNESS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SCORING SYSTEM; SENSORY DYSFUNCTION; STEADY STATE; TREATMENT OUTCOME; TURBIDIMETRY;

EID: 84879957059     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304670     Document Type: Article

References (15)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
2. Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2006;11:325-9. (Pubitemid 44730223)
3. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010;30:S84-9.
4. Anonymous. Research criteria for diagnosis of chronic in flammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:617-18.
5. Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010;81:1374-9.
6. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripheral Nerv Syst 2010;15:1-9.
7. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66:597-603.
8. Benet LZ. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc 1999;31:1642-4. (Pubitemid 29234961)
9. van Doorn PA, Kuitwaard K, Jacobs BC. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripheral Nerv Syst 2011;16:38-40.
10. Pirofsky B, Campbell SM, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. J Clin Immunol 1982;2:7S-14S. (Pubitemid 12026017)
11. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25. (Pubitemid 47327396)
12. Tackenberg B, Nimmerjahn F, Lünemann JD. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 2010;30:S65-9.
13. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 2006;26:813-27. (Pubitemid 43807633)
14. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
15. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010;67:802-7.